Abbott pays $310M for stent developer

Abbott plans to buy IDEV Technologies for $310 million, a move that will expand Abbott’s portfolio of stents for treating peripheral artery disease.

Webster, Texas-based IDEV Technologies develops endovascular technologies such as the SUPERA Veritas, a self-expanding nitinol stent system that received CE mark as a treament for PAD and was launched in Europe in 2010. In the U.S., the stent system was cleared in 2011 for palliative treatment of biliary strictures produced by malignant neoplasms. The FDA is reviewing the technology under Premarket Approval Application for treatment of the superficial femoral artery.

Abbott said it would purchase IDEV Technologies for $310 million net of cash and debt. The deal is expected close by the end of this year. Abbott is based in Abbott Park, Ill.

Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup